- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03709563
Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
May 15, 2023 updated by: DeNova Research
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of an Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss
Hair loss study in men with self-perceived thinning hair and loss
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- DeNova Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Males between 21-45 years of age, inclusive
- Have self-reported thinning or hair loss for more than 3 months prior to screening
- Clinically confirmed to have hair loss or thinning by the investigator via physical exam, including subjects with male pattern hair loss with frontal and vertex patterns II, IIIv or IV using the Norwood Hamilton Hair Loss Scale (NHS).
- In good general health, as determined by the Investigator
- Willing and able to attend all study visits
- Willing to maintain the same hair style as at the Screening Visit for the duration of the study.
- Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth)
- Be willing and able to cooperate with the requirements of the study.
- Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board.
Be able to complete and understand the various rating instruments in English.
-
Exclusion Criteria:
- Clinical diagnosis of alopecia areata or scarring forms of alopecia
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations.
- History of surgical correction of hair loss on the scalp (i.e. Hair transplant).
- Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, progesterone, and bicalutamide) within 3 months prior to the Baseline Visit.
- History of burning, flaking, itching, and stinging of the scalp.
- History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
- A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator may interfere with the study treatment.
- A known history of depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator.
- Recent utilization of low level lasers for hair growth.
- Any condition that the Investigator thinks may put the Subject at risk or interfere with their participation in the study.
- Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
Use of any medications that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator.
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo.
Take 4 capsules by mouth daily with a meal
|
Active Comparator: Oral Nutraceutical Supplement
|
Standardized Botanicals.
Take 4 capsules by mouth daily with a meal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hair counts
Time Frame: Day 90, 180, 270, 360
|
The change in vellus and terminal hair counts / average number of hairs (N/cm2) within 2 ROIs
|
Day 90, 180, 270, 360
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Shaft Thickness
Time Frame: Day 90, 180, 270, 360
|
Day 90, 180, 270, 360
|
Hair density
Time Frame: Day 90, 180, 270, 360
|
Day 90, 180, 270, 360
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 15, 2018
Primary Completion (Actual)
March 1, 2021
Study Completion (Actual)
June 1, 2021
Study Registration Dates
First Submitted
October 15, 2018
First Submitted That Met QC Criteria
October 15, 2018
First Posted (Actual)
October 17, 2018
Study Record Updates
Last Update Posted (Actual)
May 16, 2023
Last Update Submitted That Met QC Criteria
May 15, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HAIR 2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hair Loss
-
University of British ColumbiaCompletedFemale Pattern Hair LossCanada
-
HistogenCompleted
-
Sohag UniversityCompleted
-
China Medical University HospitalCompleted
-
Merz Therapeutics GmbHCompletedDiffuse Hair Loss in FemalesGermany
-
Applied Biology, Inc.CompletedAlopecia | Female Pattern Hair LossUnited States, Australia, India, Italy
-
Pak Medical and Diagnostic CenterNot yet recruitingHair Loss/Baldness
-
Duke UniversityCompletedAndrogenetic Alopecia | Male Pattern Hair Loss
-
Maja Kovacevic, MDWithdrawnAndrogenetic Alopecia | Female Pattern Hair LossItaly
-
University of MinnesotaWithdrawnAndrogenetic Alopecia | Male Pattern Baldness | Male Pattern Hair LossUnited States
Clinical Trials on Oral Nutraceutical Supplement
-
Universidad Católica San Antonio de MurciaCompleted
-
Universitat de LleidaLactalisRecruitingGlucose Metabolism DisordersSpain
-
H2O Health and Agriculture LLCUnknownPneumonia | DiarrheaGuatemala
-
Universidad Católica San Antonio de MurciaCompletedOsteoarthritisSpain
-
Abbott NutritionChangi General Hospital; SingHealth PolyclinicsCompletedMalnutritionSingapore
-
University of PaviaCompletedHypertension | Diabetes Mellitus, Type 2 | DyslipidemiasItaly
-
Universidad Católica San Antonio de MurciaCompleted
-
Institut Pasteur de LilleCompleted
-
University of ArkansasTerminatedSarcopenia | Immune SenescenceUnited States